Protalix BioTherapeutics (PLX) Cash & Current Investments (2010 - 2026)

Protalix BioTherapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 68.93% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (down 68.93% YoY), while the FY2025 annual figure was $16.3 million, down 53.22% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $10.8 million, down from $16.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $48.5 million in Q1 2024, with the low at $10.8 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $33.0 million (2023), against an average of $32.4 million.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments soared 100.9% in 2023, then plunged 68.93% in 2026.
• Protalix BioTherapeutics' Cash & Current Investments stood at $22.2 million in 2022, then jumped by 100.9% to $44.6 million in 2023, then slipped by 21.84% to $34.8 million in 2024, then tumbled by 53.22% to $16.3 million in 2025, then slumped by 33.76% to $10.8 million in 2026.
• Business Quant data shows PLX's Cash & Current Investments at $10.8 million in Q1 2026, $16.3 million in Q4 2025, and $29.4 million in Q3 2025.